Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity

Mikhail Binnewies; Adriana M. Mujal; Joshua L. Pollack; Alexis J. Combes; Emily A. Hardison; Kevin C. Barry; Jessica Tsui; Megan K. Ruhland; Kelly Kersten; Marwan A. Abushawish; Marko Spasic; Jonathan P. Giurintano; Vincent Chan; Adil I. Daud; Patrick Ha; Chun J. Ye; Edward W. Roberts; Matthew F. Krummel

doi:10.1016/j.cell.2019.02.005

Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4⁺ T Cell Immunity

Mikhail Binnewies, Adriana M. Mujal, Joshua L. Pollack, Alexis J. Combes, Emily A. Hardison, Kevin C. Barry, Jessica Tsui, Megan K. Ruhland, Kelly Kersten, Marwan A. Abushawish, Marko Spasic, Jonathan P. Giurintano, Vincent Chan, Adil I. Daud, Patrick Ha, Chun J. Ye, Edward W. Roberts, Matthew F. Krummel

Research output: Contribution to journal › Article › peer-review

372 Scopus citations

Abstract

A subtype of conventional dendritic cells, cDC2, are able to prime CD4⁺ T cells for antitumor functions and the presence of cDC2 in human cancer samples may serve as a predictive biomarker for survival and response to immune checkpoint blockade.

Original language	English (US)
Pages (from-to)	556-571.e16
Journal	Cell
Volume	177
Issue number	3
DOIs	https://doi.org/10.1016/j.cell.2019.02.005
State	Published - Apr 18 2019
Externally published	Yes

Keywords

CD4 T cells
T cell priming
checkpoint blockade
dendritic cells
immunotherapy
regulatory T cells
tumor immunology
tumor microenvironment

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.cell.2019.02.005

Cite this

Binnewies, M., Mujal, A. M., Pollack, J. L., Combes, A. J., Hardison, E. A., Barry, K. C., Tsui, J., Ruhland, M. K., Kersten, K., Abushawish, M. A., Spasic, M., Giurintano, J. P., Chan, V., Daud, A. I., Ha, P., Ye, C. J., Roberts, E. W., & Krummel, M. F. (2019). Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4⁺ T Cell Immunity. Cell, 177(3), 556-571.e16. https://doi.org/10.1016/j.cell.2019.02.005

Binnewies, M, Mujal, AM, Pollack, JL, Combes, AJ, Hardison, EA, Barry, KC, Tsui, J, Ruhland, MK, Kersten, K, Abushawish, MA, Spasic, M, Giurintano, JP, Chan, V, Daud, AI, Ha, P, Ye, CJ, Roberts, EW & Krummel, MF 2019, 'Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4⁺ T Cell Immunity', Cell, vol. 177, no. 3, pp. 556-571.e16. https://doi.org/10.1016/j.cell.2019.02.005

@article{06ab0e4e6adb4c34983d100eee97e0aa,

title = "Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity",

abstract = "A subtype of conventional dendritic cells, cDC2, are able to prime CD4+ T cells for antitumor functions and the presence of cDC2 in human cancer samples may serve as a predictive biomarker for survival and response to immune checkpoint blockade.",

keywords = "CD4 T cells, T cell priming, checkpoint blockade, dendritic cells, immunotherapy, regulatory T cells, tumor immunology, tumor microenvironment",

author = "Mikhail Binnewies and Mujal, {Adriana M.} and Pollack, {Joshua L.} and Combes, {Alexis J.} and Hardison, {Emily A.} and Barry, {Kevin C.} and Jessica Tsui and Ruhland, {Megan K.} and Kelly Kersten and Abushawish, {Marwan A.} and Marko Spasic and Giurintano, {Jonathan P.} and Vincent Chan and Daud, {Adil I.} and Patrick Ha and Ye, {Chun J.} and Roberts, {Edward W.} and Krummel, {Matthew F.}",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = apr,

day = "18",

doi = "10.1016/j.cell.2019.02.005",

language = "English (US)",

volume = "177",

pages = "556--571.e16",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity

AU - Binnewies, Mikhail

AU - Mujal, Adriana M.

AU - Pollack, Joshua L.

AU - Combes, Alexis J.

AU - Hardison, Emily A.

AU - Barry, Kevin C.

AU - Tsui, Jessica

AU - Ruhland, Megan K.

AU - Kersten, Kelly

AU - Abushawish, Marwan A.

AU - Spasic, Marko

AU - Giurintano, Jonathan P.

AU - Chan, Vincent

AU - Daud, Adil I.

AU - Ha, Patrick

AU - Ye, Chun J.

AU - Roberts, Edward W.

AU - Krummel, Matthew F.

PY - 2019/4/18

Y1 - 2019/4/18

N2 - A subtype of conventional dendritic cells, cDC2, are able to prime CD4+ T cells for antitumor functions and the presence of cDC2 in human cancer samples may serve as a predictive biomarker for survival and response to immune checkpoint blockade.

AB - A subtype of conventional dendritic cells, cDC2, are able to prime CD4+ T cells for antitumor functions and the presence of cDC2 in human cancer samples may serve as a predictive biomarker for survival and response to immune checkpoint blockade.

KW - CD4 T cells

KW - T cell priming

KW - checkpoint blockade

KW - dendritic cells

KW - immunotherapy

KW - regulatory T cells

KW - tumor immunology

KW - tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85064280433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064280433&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2019.02.005

DO - 10.1016/j.cell.2019.02.005

M3 - Article

C2 - 30955881

AN - SCOPUS:85064280433

SN - 0092-8674

VL - 177

SP - 556-571.e16

JO - Cell

JF - Cell

IS - 3

ER -